Other products in the same Health Canada class (S01A, S01AE) — coverage varies; not interchangeable
Gatifloxacin (Zymar (with preservative)): not a benefit
Moxifloxacin (Vigamox): not a benefit
Framycetin (Soframycin): general benefit
Gentamicin (Garamycin): general benefit
Bacitracin zinc + polymyxin b (Polysporin): general benefit
Tobramycin (Tobrex): general benefit
Ocuflox · DIN 02143291 · 0.3% · Oph Sol
Limited Use — Reason for Use code 170 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 170 required
Write on scriptLU code 170 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 170
Reason for Use code 170
For the treatment of conjunctivitis caused by susceptible strain(s) of Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae and Hemophilus influenzae which is/are resistant or unresponsive to listed alternative agents.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Ocuflox · DIN 02143291
Manufacturer: Allergan Inc.; listing date 1996-12-19
Health Canada: Marketed since 2024-05-27 · brand OCUFLOX · ATC S01AE01 OFLOXACIN · form Solution · route Ophthalmic · ingredients OFLOXACIN 0.3 %/W/V · company Abbvie corporation · schedule Prescription
Ocuflox: Formulary list price $2.8720/unit (unit not stated in source; not the patient's cost)
Ministry pays: $2.8720 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18491 · Verify on the e-Formulary ↗ (DIN 02143291)
Source record
DIN 02143291: Ocuflox
Raw flags: sec12=Y, sec3=Y
Item: 520412008; group id 587; item number 1544; lccId 00080; manufacturer id ALL
Source form: Oph Sol; strength: 0.3%
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $2.8720; ministry $2.8720
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02143291
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18491
Shortage status: active shortage (reported 2025-08-12, estimated to end 2026-10-09, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02143291
Shortage record checked 2026-09-13T08:10:21.292534+00:00
CIPROFLOXACIN
Form:
23 of 23 products shown
20 general benefit · 1 Limited Use · 2 not a benefit
Other products in the same Health Canada class (S01A, S01AE) — coverage varies; not interchangeable
Gatifloxacin (Zymar (with preservative)): not a benefit
Moxifloxacin (Vigamox): not a benefit
Framycetin (Soframycin): general benefit
Gentamicin (Garamycin): general benefit
Bacitracin zinc + polymyxin b (Polysporin): general benefit
Tobramycin (Tobrex): general benefit
Cipro · DIN 02237514 · 10g/100mL · Oral suspension
Limited Use — Reason for Use code 533 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 533 required
Write on scriptLU code 533 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 533
Reason for Use code 533
For patients who are unable to swallow or tolerate solid oral dosage forms.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Cipro · DIN 02237514
Manufacturer: Bayer Inc., Consumer Care Division; listing date 2001-03-07
Daily cost (source): $5.7560
Health Canada: Marketed since 1998-09-15 · brand CIPRO ORAL SUSPENSION · ATC J01MA02 CIPROFLOXACIN · form Suspension · route Oral · ingredients CIPROFLOXACIN 500 MG/5ML · company Bayer inc · schedule Prescription
Cipro: Formulary list price $0.5756/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5756 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60849 · Verify on the e-Formulary ↗ (DIN 02237514)
Source record
DIN 02237514: Cipro
Raw flags: sec12=Y, sec3=Y
Item: 084000050; group id 130; item number 0219; lccId 00307; manufacturer id BAY
Source form: Oral Susp; strength: 10g/100mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $0.5756; ministry $0.5756
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237514
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=60849
Shortage status: Reversed (report reversed by the reporter); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02237514
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Ciprofloxacin · DIN 02247339 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Ciprofloxacin · DIN 02247339
Manufacturer: Teva Canada Limited; listing date 2004-07-20
Daily cost (source): $0.8908
Health Canada: Marketed since 2017-10-11 · brand ACT CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250 MG · company Teva canada limited · schedule Prescription
Act Ciprofloxacin: Formulary list price $0.4454/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4454 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71582 · Verify on the e-Formulary ↗ (DIN 02247339)
Source record
DIN 02247339: Act Ciprofloxacin
Raw flags: sec3=Y
Item: 084000014; group id 131; item number 0220; lccId None; manufacturer id TEV
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4454; ministry $0.4454
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247339
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71582Interchangeable products
Apo-Ciproflox · DIN 02229521 · $0.4454
Auro-Ciprofloxacin · DIN 02381907 · $0.4454
Cipro · DIN 02155958 · not recorded
Ciprofloxacin · DIN 02353318 · $0.4454
Ciprofloxacin · DIN 02386119 · $0.4454
Jamp-Ciprofloxacin · DIN 02380358 · $0.4454
Mar-Ciprofloxacin · DIN 02379686 · $0.4454
Mint-Ciproflox · DIN 02423553 · $0.4454
PMS-Ciprofloxacin · DIN 02248437 · $0.4454
Ran-Ciproflox · DIN 02303728 · $0.4454
Ratio-Ciprofloxacin · DIN 02246825 · $0.4454
Sandoz Ciprofloxacin · DIN 02248756 · $0.4454
Septa-Ciprofloxacin · DIN 02379627 · $0.4454
Teva-Ciprofloxacin · DIN 02161737 · $0.4454
Shortage status: resolved shortage (ended 2023-10-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247339
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Ciprofloxacin · DIN 02381907 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Ciprofloxacin · DIN 02381907
Manufacturer: Auro Pharma Inc.; listing date 2012-08-27
Daily cost (source): $0.8908
Health Canada: Marketed since 2012-06-13 · brand AURO-CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250 MG · company Auro pharma inc · schedule Prescription
Auro-Ciprofloxacin: Formulary list price $0.4454/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4454 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86775 · Verify on the e-Formulary ↗ (DIN 02381907)
Source record
DIN 02381907: Auro-Ciprofloxacin
Raw flags: sec3=Y
Item: 084000014; group id 131; item number 0220; lccId None; manufacturer id AUR
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4454; ministry $0.4454
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381907
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86775Interchangeable products
Act Ciprofloxacin · DIN 02247339 · $0.4454
Apo-Ciproflox · DIN 02229521 · $0.4454
Cipro · DIN 02155958 · not recorded
Ciprofloxacin · DIN 02353318 · $0.4454
Ciprofloxacin · DIN 02386119 · $0.4454
Jamp-Ciprofloxacin · DIN 02380358 · $0.4454
Mar-Ciprofloxacin · DIN 02379686 · $0.4454
Mint-Ciproflox · DIN 02423553 · $0.4454
PMS-Ciprofloxacin · DIN 02248437 · $0.4454
Ran-Ciproflox · DIN 02303728 · $0.4454
Ratio-Ciprofloxacin · DIN 02246825 · $0.4454
Sandoz Ciprofloxacin · DIN 02248756 · $0.4454
Septa-Ciprofloxacin · DIN 02379627 · $0.4454
Teva-Ciprofloxacin · DIN 02161737 · $0.4454
Shortage status: resolved shortage (ended 2024-01-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02381907
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ciprofloxacin · DIN 02353318 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ciprofloxacin · DIN 02353318
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Daily cost (source): $0.8908
Health Canada: Marketed since 2026-05-14 · brand CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250 MG · company Sanis health inc · schedule Prescription
Ciprofloxacin: Formulary list price $0.4454/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4454 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83851 · Verify on the e-Formulary ↗ (DIN 02353318)
Source record
DIN 02353318: Ciprofloxacin
Raw flags: sec3=Y
Item: 084000014; group id 131; item number 0220; lccId None; manufacturer id SAI
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4454; ministry $0.4454
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353318
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83851Interchangeable products
Act Ciprofloxacin · DIN 02247339 · $0.4454
Apo-Ciproflox · DIN 02229521 · $0.4454
Auro-Ciprofloxacin · DIN 02381907 · $0.4454
Cipro · DIN 02155958 · not recorded
Ciprofloxacin · DIN 02386119 · $0.4454
Jamp-Ciprofloxacin · DIN 02380358 · $0.4454
Mar-Ciprofloxacin · DIN 02379686 · $0.4454
Mint-Ciproflox · DIN 02423553 · $0.4454
PMS-Ciprofloxacin · DIN 02248437 · $0.4454
Ran-Ciproflox · DIN 02303728 · $0.4454
Ratio-Ciprofloxacin · DIN 02246825 · $0.4454
Sandoz Ciprofloxacin · DIN 02248756 · $0.4454
Septa-Ciprofloxacin · DIN 02379627 · $0.4454
Teva-Ciprofloxacin · DIN 02161737 · $0.4454
Shortage status: resolved shortage (ended 2026-08-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353318
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ciprofloxacin · DIN 02386119 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ciprofloxacin · DIN 02386119
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Daily cost (source): $0.8908
Health Canada: Marketed since 2014-12-19 · brand CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Ciprofloxacin: Formulary list price $0.4454/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4454 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87170 · Verify on the e-Formulary ↗ (DIN 02386119)
Source record
DIN 02386119: Ciprofloxacin
Raw flags: sec3=Y
Item: 084000014; group id 131; item number 0220; lccId None; manufacturer id SIV
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4454; ministry $0.4454
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386119
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87170Interchangeable products
Act Ciprofloxacin · DIN 02247339 · $0.4454
Apo-Ciproflox · DIN 02229521 · $0.4454
Auro-Ciprofloxacin · DIN 02381907 · $0.4454
Cipro · DIN 02155958 · not recorded
Ciprofloxacin · DIN 02353318 · $0.4454
Jamp-Ciprofloxacin · DIN 02380358 · $0.4454
Mar-Ciprofloxacin · DIN 02379686 · $0.4454
Mint-Ciproflox · DIN 02423553 · $0.4454
PMS-Ciprofloxacin · DIN 02248437 · $0.4454
Ran-Ciproflox · DIN 02303728 · $0.4454
Ratio-Ciprofloxacin · DIN 02246825 · $0.4454
Sandoz Ciprofloxacin · DIN 02248756 · $0.4454
Septa-Ciprofloxacin · DIN 02379627 · $0.4454
Teva-Ciprofloxacin · DIN 02161737 · $0.4454
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386119
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Ciprofloxacin · DIN 02380358 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Ciprofloxacin · DIN 02380358
Manufacturer: Jamp Pharma Corporation; listing date 2012-09-28
Daily cost (source): $0.8908
Health Canada: Marketed since 2012-03-16 · brand JAMP-CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Ciprofloxacin: Formulary list price $0.4454/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4454 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86616 · Verify on the e-Formulary ↗ (DIN 02380358)
Source record
DIN 02380358: Jamp-Ciprofloxacin
Raw flags: sec3=Y
Item: 084000014; group id 131; item number 0220; lccId None; manufacturer id JPC
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4454; ministry $0.4454
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380358
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86616Interchangeable products
Act Ciprofloxacin · DIN 02247339 · $0.4454
Apo-Ciproflox · DIN 02229521 · $0.4454
Auro-Ciprofloxacin · DIN 02381907 · $0.4454
Cipro · DIN 02155958 · not recorded
Ciprofloxacin · DIN 02353318 · $0.4454
Ciprofloxacin · DIN 02386119 · $0.4454
Mar-Ciprofloxacin · DIN 02379686 · $0.4454
Mint-Ciproflox · DIN 02423553 · $0.4454
PMS-Ciprofloxacin · DIN 02248437 · $0.4454
Ran-Ciproflox · DIN 02303728 · $0.4454
Ratio-Ciprofloxacin · DIN 02246825 · $0.4454
Sandoz Ciprofloxacin · DIN 02248756 · $0.4454
Septa-Ciprofloxacin · DIN 02379627 · $0.4454
Teva-Ciprofloxacin · DIN 02161737 · $0.4454
Shortage status: resolved shortage (ended 2020-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02380358
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Ciprofloxacin · DIN 02379686 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Ciprofloxacin · DIN 02379686
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-05-29
Daily cost (source): $0.8908
Health Canada: Marketed since 2012-09-06 · brand MAR-CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Ciprofloxacin: Formulary list price $0.4454/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4454 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86555 · Verify on the e-Formulary ↗ (DIN 02379686)
Source record
DIN 02379686: Mar-Ciprofloxacin
Raw flags: sec3=Y
Item: 084000014; group id 131; item number 0220; lccId None; manufacturer id MAR
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4454; ministry $0.4454
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02379686
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86555Interchangeable products
Act Ciprofloxacin · DIN 02247339 · $0.4454
Apo-Ciproflox · DIN 02229521 · $0.4454
Auro-Ciprofloxacin · DIN 02381907 · $0.4454
Cipro · DIN 02155958 · not recorded
Ciprofloxacin · DIN 02353318 · $0.4454
Ciprofloxacin · DIN 02386119 · $0.4454
Jamp-Ciprofloxacin · DIN 02380358 · $0.4454
Mint-Ciproflox · DIN 02423553 · $0.4454
PMS-Ciprofloxacin · DIN 02248437 · $0.4454
Ran-Ciproflox · DIN 02303728 · $0.4454
Ratio-Ciprofloxacin · DIN 02246825 · $0.4454
Sandoz Ciprofloxacin · DIN 02248756 · $0.4454
Septa-Ciprofloxacin · DIN 02379627 · $0.4454
Teva-Ciprofloxacin · DIN 02161737 · $0.4454
Shortage status: resolved shortage (ended 2020-01-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02379686
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Ciproflox · DIN 02303728 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Ciproflox · DIN 02303728
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2008-03-25
Daily cost (source): $0.8908
Health Canada: Marketed since 2020-03-11 · brand TARO-CIPROFLOX · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250 MG · company Sun pharma canada inc · schedule Prescription
Ran-Ciproflox: Formulary list price $0.4454/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4454 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78902 · Verify on the e-Formulary ↗ (DIN 02303728)
Source record
DIN 02303728: Ran-Ciproflox
Raw flags: sec3=Y
Item: 084000014; group id 131; item number 0220; lccId None; manufacturer id RAN
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4454; ministry $0.4454
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02303728
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78902Interchangeable products
Act Ciprofloxacin · DIN 02247339 · $0.4454
Apo-Ciproflox · DIN 02229521 · $0.4454
Auro-Ciprofloxacin · DIN 02381907 · $0.4454
Cipro · DIN 02155958 · not recorded
Ciprofloxacin · DIN 02353318 · $0.4454
Ciprofloxacin · DIN 02386119 · $0.4454
Jamp-Ciprofloxacin · DIN 02380358 · $0.4454
Mar-Ciprofloxacin · DIN 02379686 · $0.4454
Mint-Ciproflox · DIN 02423553 · $0.4454
PMS-Ciprofloxacin · DIN 02248437 · $0.4454
Ratio-Ciprofloxacin · DIN 02246825 · $0.4454
Sandoz Ciprofloxacin · DIN 02248756 · $0.4454
Septa-Ciprofloxacin · DIN 02379627 · $0.4454
Teva-Ciprofloxacin · DIN 02161737 · $0.4454
Shortage status: active shortage (reported 2026-04-01, estimated to end 2026-11-20, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02303728
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Ciprofloxacin · DIN 02248756 · 250mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Ciprofloxacin · DIN 02248756
Manufacturer: Sandoz Canada Inc.; listing date 2004-07-20
Daily cost (source): $0.8908
Health Canada: Marketed since 2005-12-01 · brand SANDOZ CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 250 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Ciprofloxacin: Formulary list price $0.4454/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4454 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73124 · Verify on the e-Formulary ↗ (DIN 02248756)
Source record
DIN 02248756: Sandoz Ciprofloxacin
Raw flags: sec3=Y
Item: 084000014; group id 131; item number 0220; lccId None; manufacturer id SDZ
Source form: Tab; strength: 250mg
Recorded listing: General benefit
Source prices (unrounded): $0.4454; ministry $0.4454
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248756
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73124Interchangeable products
Act Ciprofloxacin · DIN 02247339 · $0.4454
Apo-Ciproflox · DIN 02229521 · $0.4454
Auro-Ciprofloxacin · DIN 02381907 · $0.4454
Cipro · DIN 02155958 · not recorded
Ciprofloxacin · DIN 02353318 · $0.4454
Ciprofloxacin · DIN 02386119 · $0.4454
Jamp-Ciprofloxacin · DIN 02380358 · $0.4454
Mar-Ciprofloxacin · DIN 02379686 · $0.4454
Mint-Ciproflox · DIN 02423553 · $0.4454
PMS-Ciprofloxacin · DIN 02248437 · $0.4454
Ran-Ciproflox · DIN 02303728 · $0.4454
Ratio-Ciprofloxacin · DIN 02246825 · $0.4454
Septa-Ciprofloxacin · DIN 02379627 · $0.4454
Teva-Ciprofloxacin · DIN 02161737 · $0.4454
Shortage status: resolved shortage (ended 2025-09-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248756
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Act Ciprofloxacin · DIN 02247340 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Act Ciprofloxacin · DIN 02247340
Manufacturer: Teva Canada Limited; listing date 2004-07-20
Daily cost (source): $1.0050
Health Canada: Marketed since 2017-10-11 · brand ACT CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Teva canada limited · schedule Prescription
Act Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71583 · Verify on the e-Formulary ↗ (DIN 02247340)
Source record
DIN 02247340: Act Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id TEV
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02247340
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71583Interchangeable products
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: resolved shortage (ended 2026-03-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247340
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Ciprofloxacin · DIN 02381923 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Ciprofloxacin · DIN 02381923
Manufacturer: Auro Pharma Inc.; listing date 2012-08-27
Daily cost (source): $1.0050
Health Canada: Marketed since 2012-06-13 · brand AURO-CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Auro pharma inc · schedule Prescription
Auro-Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86776 · Verify on the e-Formulary ↗ (DIN 02381923)
Source record
DIN 02381923: Auro-Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id AUR
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381923
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86776Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: resolved shortage (ended 2024-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02381923
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ciprofloxacin · DIN 02353326 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ciprofloxacin · DIN 02353326
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Daily cost (source): $1.0050
Health Canada: Marketed since 2026-05-14 · brand CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Sanis health inc · schedule Prescription
Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83852 · Verify on the e-Formulary ↗ (DIN 02353326)
Source record
DIN 02353326: Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id SAI
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02353326
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83852Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: shortage reported ended 2026-08-18 (report last updated 2026-08-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353326
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ciprofloxacin · DIN 02386127 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ciprofloxacin · DIN 02386127
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30
Daily cost (source): $1.0050
Health Canada: Marketed since 2014-12-19 · brand CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87171 · Verify on the e-Formulary ↗ (DIN 02386127)
Source record
DIN 02386127: Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id SIV
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02386127
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87171Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02386127
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ciprofloxacin · DIN 02547147 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ciprofloxacin · DIN 02547147
Manufacturer: DAC Pharmaceuticals; listing date 2026-05-29
Daily cost (source): $1.0050
Health Canada: Marketed since 2025-02-26 · brand CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company 10445517 canada inc / north pharmaceuticals / dac pharmaceuticals · schedule Prescription
Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103580 · Verify on the e-Formulary ↗ (DIN 02547147)
Source record
DIN 02547147: Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id DAC
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02547147
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103580Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02547147
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp-Ciprofloxacin · DIN 02380366 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jamp-Ciprofloxacin · DIN 02380366
Manufacturer: Jamp Pharma Corporation; listing date 2012-09-28
Daily cost (source): $1.0050
Health Canada: Marketed since 2012-03-16 · brand JAMP-CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86617 · Verify on the e-Formulary ↗ (DIN 02380366)
Source record
DIN 02380366: Jamp-Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id JPC
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380366
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86617Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: resolved shortage (ended 2020-03-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02380366
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mar-Ciprofloxacin · DIN 02379694 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mar-Ciprofloxacin · DIN 02379694
Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2012-05-29
Daily cost (source): $1.0050
Health Canada: Marketed since 2012-09-06 · brand MAR-CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Marcan pharmaceuticals inc · schedule Prescription
Mar-Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86556 · Verify on the e-Formulary ↗ (DIN 02379694)
Source record
DIN 02379694: Mar-Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id MAR
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02379694
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86556Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: resolved shortage (ended 2024-04-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02379694
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mint-Ciproflox · DIN 02423561 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Ciproflox · DIN 02423561
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-07-30
Daily cost (source): $1.0050
Health Canada: Marketed since 2020-03-20 · brand MINT-CIPROFLOX · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Ciproflox: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90828 · Verify on the e-Formulary ↗ (DIN 02423561)
Source record
DIN 02423561: Mint-Ciproflox
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id MIN
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423561
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90828Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: resolved shortage (ended 2020-03-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02423561
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Ciprofloxacin · DIN 02492008 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
NRA-Ciprofloxacin · DIN 02492008
Manufacturer: Nora Pharma; listing date 2021-02-26
Daily cost (source): $1.0050
Health Canada: Marketed since 2020-12-03 · brand NRA-CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Nora pharma inc · schedule Prescription
NRA-Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98201 · Verify on the e-Formulary ↗ (DIN 02492008)
Source record
DIN 02492008: NRA-Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id NRA
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02492008
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98201Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02492008
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Ciprofloxacin · DIN 02248438 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Ciprofloxacin · DIN 02248438
Manufacturer: Pharmascience Inc.; listing date 2004-07-20
Daily cost (source): $1.0050
Health Canada: Marketed since 2004-02-18 · brand PMS-CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Pharmascience inc · schedule Prescription
PMS-Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72789 · Verify on the e-Formulary ↗ (DIN 02248438)
Source record
DIN 02248438: PMS-Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id PMS
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248438
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72789Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: resolved shortage (ended 2019-07-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248438
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ran-Ciproflox · DIN 02303736 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Ran-Ciproflox · DIN 02303736
Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2008-03-25
Daily cost (source): $1.0050
Health Canada: Marketed since 2020-03-11 · brand TARO-CIPROFLOX · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Sun pharma canada inc · schedule Prescription
Ran-Ciproflox: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78903 · Verify on the e-Formulary ↗ (DIN 02303736)
Source record
DIN 02303736: Ran-Ciproflox
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id RAN
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02303736
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78903Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Sandoz Ciprofloxacin · DIN 02248757 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: active shortage (reported 2025-12-01, estimated to end 2026-09-11, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02303736
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Ciprofloxacin · DIN 02248757 · 500mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Sandoz Ciprofloxacin · DIN 02248757
Manufacturer: Sandoz Canada Inc.; listing date 2004-07-20
Daily cost (source): $1.0050
Health Canada: Marketed since 2005-12-01 · brand SANDOZ CIPROFLOXACIN · ATC J01MA02 CIPROFLOXACIN · form Tablet · route Oral · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 500 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Ciprofloxacin: Formulary list price $0.5025/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.5025 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73125 · Verify on the e-Formulary ↗ (DIN 02248757)
Source record
DIN 02248757: Sandoz Ciprofloxacin
Raw flags: sec3=Y
Item: 084000015; group id 131; item number 0221; lccId None; manufacturer id SDZ
Source form: Tab; strength: 500mg
Recorded listing: General benefit
Source prices (unrounded): $0.5025; ministry $0.5025
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248757
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73125Interchangeable products
Act Ciprofloxacin · DIN 02247340 · $0.5025
Apo-Ciproflox · DIN 02229522 · $0.5025
Auro-Ciprofloxacin · DIN 02381923 · $0.5025
Cipro · DIN 02155966 · not recorded
Ciprofloxacin · DIN 02353326 · $0.5025
Ciprofloxacin · DIN 02386127 · $0.5025
Ciprofloxacin · DIN 02547147 · $0.5025
Jamp-Ciprofloxacin · DIN 02380366 · $0.5025
Mar-Ciprofloxacin · DIN 02379694 · $0.5025
Mint-Ciproflox · DIN 02423561 · $0.5025
NRA-Ciprofloxacin · DIN 02492008 · $0.5025
PMS-Ciprofloxacin · DIN 02248438 · $0.5025
Ran-Ciproflox · DIN 02303736 · $0.5025
Ratio-Ciprofloxacin · DIN 02246826 · $0.5025
Septa-Ciprofloxacin · DIN 02379635 · $0.5025
Shortage status: resolved shortage (ended 2023-10-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248757
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Ciloxan · DIN 01945270 · 0.3% · Oph Sol-5mL Pk
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ciloxan · DIN 01945270
Manufacturer: Novartis Pharma Canada Inc.; listing date 2009-01-30
Health Canada: Marketed since 2018-10-15 · brand CILOXAN · ATC S03AA07 CIPROFLOXACIN · form Solution · route Ophthalmic · ingredients CIPROFLOXACIN (CIPROFLOXACIN HYDROCHLORIDE) 0.3 %/W/V · company Novartis pharmaceuticals canada inc · schedule Prescription
Ciloxan: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12953 · Verify on the e-Formulary ↗ (DIN 01945270)
Source record
DIN 01945270: Ciloxan
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520412012; group id 586; item number 1543; lccId None; manufacturer id NOV
Source form: Oph Sol-5mL Pk; strength: 0.3%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01945270
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12953Interchangeable products
Apo-Ciproflox · DIN 02263130 · not recorded
Sandoz Ciprofloxacin · DIN 02387131 · not recorded
Shortage status: discontinued (2026-03-17, reported by NOVARTIS PHARMACEUTICALS CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01945270
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87272 · Verify on the e-Formulary ↗ (DIN 02387131)
Source record
DIN 02387131: Sandoz Ciprofloxacin
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 520412012; group id 586; item number 1543; lccId None; manufacturer id SDZ
Source form: Oph Sol-5mL Pk; strength: 0.3%
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $9.3000; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02387131
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87272Interchangeable products
Apo-Ciproflox · DIN 02263130 · not recorded
Ciloxan · DIN 01945270 · not recorded
Shortage status: discontinued (2026-03-09, reported by SANDOZ CANADA INCORPORATED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02387131
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM, TRIMETHOPRIM
08:40 Miscellaneous Anti-Infectives
Other drugs in the same formulary class (52:04:04 Antibiotics) and how they are covered
Matched class: 52:04:04 Antibiotics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: FRAMYCETIN SULFATE, FRAMYCETIN SULFATE & GRAMICIDIN & DEXAMETHASONE, GENTAMICIN & BETAMETHASONE SODIUM PHOSPHATE, GENTAMICIN SULFATE, POLYMYXIN B SULFATE & BACITRACIN (ZINC), POLYMYXIN B SULFATE & GRAMICIDIN, TOBRAMYCIN, TOBRAMYCIN & DEXAMETHASONE
52:04:04 Antibiotics
Other drugs in the same formulary class (52:04:12 Other Anti-Infectives) and how they are covered
No products matched this class search: “52:04:12”.
This is a search result, not a decision about coverage. Try a different class name, abbreviation or class code.
Search this as a medication name or DIN
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
CLARITHROMYCIN · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), General benefit (15), Off-Formulary Interchangeable, not an ODB benefit (9)
(For additional information on the use of BIAXIN BID® in triple therapy for the treatment of
H. pylori infection and active duodenal ulcer recurrence, refer to the Hp-PAC® Product
Monograph.)
BIAXIN® (clarithromycin for oral suspension USP)
Product Monograph Master Template Template Date: September 2020
BIAXIN BID®, BIAXIN® - clarithromycin Page 4 of 107
BIAXIN® is indicated for the treatment of infections due to susceptible organisms, in the following
conditions:
• Upper Respiratory Tract
• Pharyngitis caused by S. pyogenes (Group A ß-hemolytic streptococci).
PM: https://pdf.hres.ca/dpd_pm/00078094.PDF; date DEC 17, 2024; DIN 01984853; fetched 2026-09-10
Product monographTETRACYCLINE · Listed, not a benefit (1), General benefit (1)
Indications
TETRACYCLINE (tetracycline hydrochloride capsules) is indicated for infections caused by the following
microorganisms:
• Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever,
rickettsialpox, tick fevers), M. pneumoniae (PPLO, Eaton agent), agents of psittacosis and ornithosis,
agents of L. venereum and G. inguinale, and the spirochetal agent of relapsing fever (B. recurrentis).
PM: https://pdf.hres.ca/dpd_pm/00084169.PDF; date 2026-03-17; DIN 00580929; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS
OCUFLOX® (ofloxacin) is indicated for the treatment of conjunctivitis when caused by susceptible
strains of the following bacteria:
Gram Positive Bacteria
• Staphylococcus aureus
• Staphylococcus epidermidis
• Streptococcus pneumoniae
Gram Negative Bacteria
• Haemophilus influenza
To reduce the development of drug-resistant bacteria and maintain the effectiveness of OCUFLOX and
other antibacterial drugs, OCUFLOX should be used only to treat infections that are proven or strongly
suspected to be caused by bacteria.
1.1 Pediatrics
Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety
and efficacy of OCUFLOX in pediatric patients has not been established. Therefore, Health Canada has
not authorized an indication for pediatric use. See 7.1.3 Pediatrics.
1.2 Geriatrics
Geriatrics (> 65 years of age): No comparative data are available to Health Canada; therefore, Health
Canada has not authorized an indication for geriatric use.
https://pdf.hres.ca/dpd_pm/00067076.PDF
PM date: NOV 25, 1994
Source product: OCUFLOX; DIN 02143291; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
CILOXAN® (ciprofloxacin ophthalmic solution) is indicated for the treatment of the following
infections of the eye and its adnexae when caused by susceptible strains of the designated bacteria.
Corneal Ulcers: Pseudomonas aeruginosa, Staphylococcus aureus,
Staphylococcus epidermidis, Streptococcus pneumoniae.
Conjunctivitis: Staphylococcus aureus, Staphylococcus epidermidis,
Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus
influenzae.
CILOXAN® (ciprofloxacin ophthalmic ointment) is indicated for the treatment of the following
infections of the eye and its adnexae when caused by susceptible strains of the designated bacteria.
Corneal Ulcers: Pseudomonas aeruginosa, Staphylococcus aureus,
Staphylococcus epidermidis.
Conjunctivitis: Staphylococcus aureus, Staphylococcus epidermidis,
Streptococcus (Viridans group), Streptococcus pneumoniae, Haemophilus
influenzae.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CILOXAN and
other antibac…
https://pdf.hres.ca/dpd_pm/00045906.PDF
PM date: May 22, 2018
Source product: CILOXAN; DIN 01945270; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
1 INDICATIONS
APO-LEVOFLOXACIN (levofloxacin tablets) are indicated for the treatment of adults with
bacterial infections caused by susceptible strains of the designated microorganisms in the
infections listed below.
• To reduce the development of drug-resistant bacteria and maintain the effectiveness of
APO- LEVOFLOXACIN and other antibacterial drugs, APO-LEVOFLOXACIN should be used
only to treat infections that are proven or strongly suspected to be caused by susceptible
bacteria. When culture and susceptibility information are available, they should be
considered in selecting or modifying antibacterial therapy. In the absence of such data, local
epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
• Upper Respiratory Tract
Acute bacterial sinusitis (mild to moderate) due to Streptococcus pneumoniae, Haemophilus
influenzae, or Moraxella (Branhamella) catarrhalis.
Restrict the use of APO-LEVOFLOXACIN to settings where no other treatment options exist,
and the clinical presentation meets the diagnostic criteria for acute bacterial sinusitis.1
• Lower Respiratory Tract
Acute bacterial exacerbations of chronic bron…
https://pdf.hres.ca/dpd_pm/00078730.PDF
PM date: JUN 24, 2009
Source product: APO-LEVOFLOXACIN; DIN 02284707; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
CIPRODEX® (ciprofloxacin/dexamethasone otic suspension) is indicated for the treatment of
infections caused by most strains of the designated microorganisms in the specific conditions
listed below:
Acute Otitis Media with Otorrhea through tympanostomy tubes in pediatric patients ≥ 6
months of age due to:
Aerobic, Gram-Positive:
Streptococcus pneumoniae
Staphylococcus aureus
Aerobic, Gram-Negative:
Haemophilus influenza
Moraxella catarrhalis
Pseudomonas aeruginosa
Acute Otitis Externa in adults and pediatric patients ≥ 1 year of age due to:
Aerobic, Gram-Positive:
Staphylococcus aureus
Aerobic, Gram-Negative:
Pseudomonas aeruginosa
To reduce the development of drug-resistant bacteria and maintain the effectiveness of
CIPRODEX and other antibacterial drugs, CIPRODEX should be used only to treat infections
that are proven or strongly suspected to be caused by susceptible bacteria.
CIPRODEX® Product Monograph Page 3 of 20
Geriatrics (> 65 years of age): Elderly patients may be at a higher risk of developing tendon
inflammation and rupture (see WARNINGS AND PRECAUTIONS, General).
Pediatrics (…
https://pdf.hres.ca/dpd_pm/00041611.PDF
PM date: September 27, 2017
Source product: CIPRODEX; DIN 02252716; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
Availability
Ocuflox · DIN 02143291
Shortage status: active shortage (reported 2025-08-12, estimated to end 2026-10-09, last updated 2026-09-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02143291
Ran-Ciproflox · DIN 02303728
Shortage status: active shortage (reported 2026-04-01, estimated to end 2026-11-20, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02303728
Ciprofloxacin · DIN 02353326
Shortage status: shortage reported ended 2026-08-18 (report last updated 2026-08-18); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02353326
Ran-Ciproflox · DIN 02303736
Shortage status: active shortage (reported 2025-12-01, estimated to end 2026-09-11, last updated 2026-09-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02303736
For Ciloxan, Sandoz Ciprofloxacin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.